Latest Conference Articles

An expert explained the importance of understanding different subtypes of metastatic breast cancer and available treatment options based on biomarker testing.

Here are answers to 10 questions patients asked at the CURE® Educated Patient® Metastatic Breast Cancer Summit about scans, treatment and clinical trials.

Before enrolling in a clinical trial for metastatic breast cancer, it’s important to know which are best suited for each individual, an expert said.

One specialist explained the ways palliative care, also known as supportive care, can assist patients during a breast cancer journey.

At the CURE® Educated Patient® Breast Cancer Summit, an expert discussed integrative methods that can improve quality of life.

Patients with HR-positive metastatic breast cancer can expect to undergo biomarker testing both at diagnosis and again if the disease progresses.

One expert explained the common side effects at every line of treatment for metastatic HER2-positive breast cancer during the CURE® Educated Patient® Metastatic Breast Cancer Summit.

One expert explains why “the future of precision medicine” has arrived in lung cancer at the CURE® Educated Patient® Lung Cancer Summit.

Tumor characteristics are used to determine the best method of combining therapies with surgery for non-small cell lung cancer, according to a presentation at the CURE® Educated Patient® Lung Cancer Summit.

Radiation plus targeted or immunotherapies could be beneficial for certain patients with lung cancer, and expert said at the CURE® Educated Patient® Lung Cancer Summit.

Patients with lung cancer may have personalized treatment options after biomarker testing, an expert said at the CURE® Educated Patient® Lung Cancer Summit.

Treatment for lung cancer has changed significantly with immunotherapy, an expert said during the CURE® Educated Patient® Lung Cancer Summit.

Data show that patients’ multiple myeloma still fails to progress if patients receive less-frequent Tecvayli.

To ensure best outcomes, patients with chronic myeloid leukemia should maintain frequent communication with their care teams — even between appointments.

Most — though not all — side effects from chronic myeloid leukemia treatment improve over time, an expert said.

A chronic myeloid leukemia diagnosis can negatively affect patients and their loved ones’ mental health, but there are resources that can help.

As part of the CURE® Educated Patient® Summit, one expert reviewed the landscape of bispecific antibodies, such as Tecvayli, for multiple myeloma.

Patients with chronic myeloid leukemia should be upfront with their care team about how treatment side effects are affecting their daily functioning.

Quality of life may temporarily worsen after patients with myeloma receive stem cell transplants, said an expert at the Educated Patient® Multiple Myeloma Summit.

Initial discussions about treatment, side effects and study results can help patients navigate through all aspects of a chronic myeloid leukemia diagnosis.

An advocate discusses vital patient-provider conversations to promote the best care for individuals with chronic myeloid leukemia.

For patients with non-small lung cancer and brain metastases, it’s important to consent to shaving the scalp before tumor-treating fields therapy.

New drug combinations and sequences are being investigated and may improve outcomes for patients with newly diagnosed myeloma, an expert explained at the Educated Patient® Multiple Myeloma Summit.

Data from the MajesTEC-1 trial shows that patients with relapsed/refractory multiple myeloma responded to Tecvalyi for a median of two years and lived without disease progression for nearly a year.

Sarclisa, Velcade, Revlimid and dexamethasone improved progression-free survival in patients with multiple myeloma who were not eligible for transplant.

Patients with resectable stage 3 melanoma should talk about pretreatment therapy with their cancer care teams, an expert said.

Padcev and Keytruda improve survival and progression among patients with bladder cancer, but don’t adversely impact pain, functioning or quality of life.

Trodelvy led to better disease control and improved quality of life compared to chemotherapy in patients with triple-negative breast cancer.